These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 23904555)

  • 1. Mesothelin and osteopontin.
    Hillerdal G
    Eur Respir J; 2013 Aug; 42(2):557. PubMed ID: 23904555
    [No Abstract]   [Full Text] [Related]  

  • 2. Mesothelin and osteopontin.
    Pantazopoulos I; Xanthos T; Boura P; Syrigos K
    Eur Respir J; 2013 Aug; 42(2):557-8. PubMed ID: 23904556
    [No Abstract]   [Full Text] [Related]  

  • 3. Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma.
    Pantazopoulos I; Boura P; Xanthos T; Syrigos K
    Eur Respir J; 2013 Mar; 41(3):706-15. PubMed ID: 22835614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
    Grigoriu BD; Scherpereel A; Devos P; Chahine B; Letourneux M; Lebailly P; Grégoire M; Porte H; Copin MC; Lassalle P
    Clin Cancer Res; 2007 May; 13(10):2928-35. PubMed ID: 17504993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Other thoracic cancers. Malignant pleural mesothelioma: biology and diagnosis].
    Scherpereel A; Grigoriu BD; Astoul P
    Rev Mal Respir; 2008 Oct; 25(8 Pt 2):3S183-90. PubMed ID: 18971844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma--which is best?
    Creaney J; Yeoman D; Musk AW; de Klerk N; Skates SJ; Robinson BW
    Lung Cancer; 2011 Oct; 74(1):55-60. PubMed ID: 21397972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.
    Creaney J; Yeoman D; Demelker Y; Segal A; Musk AW; Skates SJ; Robinson BW
    J Thorac Oncol; 2008 Aug; 3(8):851-7. PubMed ID: 18670302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New diagnostic markers for malignant pleural mesothelioma].
    Grigoriu BD; Grégoire M; Chahine B; Scherpereel A
    Bull Cancer; 2008 Feb; 95(2):177-84. PubMed ID: 18304902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study.
    Bruno F; Baratti D; Martinetti A; Morelli D; Sottotetti E; Bonini C; Guaglio M; Kusamura S; Deraco M
    Eur J Surg Oncol; 2018 Jun; 44(6):792-798. PubMed ID: 29503128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pleural fluid mesothelin as an adjunct to the diagnosis of pleural malignant mesothelioma.
    Creaney J; Segal A; Olsen N; Dick IM; Musk AW; Skates SJ; Robinson BW
    Dis Markers; 2014; 2014():413946. PubMed ID: 25505814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology.
    Canessa PA; Franceschini MC; Ferro P; Battolla E; Dessanti P; Manta C; Sivori M; Pezzi R; Fontana V; Fedeli F; Pistillo MP; Roncella S
    Cancer Invest; 2013 Jan; 31(1):43-50. PubMed ID: 23249166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma.
    Cristaudo A; Bonotti A; Simonini S; Vivaldi A; Guglielmi G; Ambrosino N; Chella A; Lucchi M; Mussi A; Foddis R
    J Thorac Oncol; 2011 Sep; 6(9):1587-93. PubMed ID: 21642872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hunting for a pleural fluid test for mesothelioma: is soluble mesothelin the answer?
    Lee YC
    Thorax; 2007 Jul; 62(7):561-2. PubMed ID: 17600291
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma.
    Yamada S; Tabata C; Tabata R; Fukuoka K; Nakano T
    Clin Chem Lab Med; 2011 Oct; 49(10):1721-6. PubMed ID: 21692685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical utility of diagnostic markers for malignant pleural mesothelioma.
    Grigoriu BD; Grigoriu C; Chahine B; Gey T; Scherpereel A
    Monaldi Arch Chest Dis; 2009 Mar; 71(1):31-8. PubMed ID: 19522163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum and pleural fluid biomarkers for mesothelioma.
    Creaney J; Robinson BW
    Curr Opin Pulm Med; 2009 Jul; 15(4):366-70. PubMed ID: 19417672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostication and monitoring of mesothelioma using biomarkers: a systematic review.
    Arnold DT; De Fonseka D; Hamilton FW; Rahman NM; Maskell NA
    Br J Cancer; 2017 Mar; 116(6):731-741. PubMed ID: 28170372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels.
    Rai AJ; Flores RM; Mathew A; Gonzalez-Espinoza R; Bott M; Ladanyi M; Rusch V; Fleisher M
    Clin Chem Lab Med; 2010 Feb; 48(2):271-8. PubMed ID: 20131968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of the monoclonal antibody mesothelin in the diagnosis of malignant mesothelioma in pleural biopsies.
    Galloway ML; Murray D; Moffat DF
    Histopathology; 2006 May; 48(6):767-9. PubMed ID: 16681698
    [No Abstract]   [Full Text] [Related]  

  • 20. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.
    Creaney J; van Bruggen I; Hof M; Segal A; Musk AW; de Klerk N; Horick N; Skates SJ; Robinson BW
    Chest; 2007 Oct; 132(4):1239-46. PubMed ID: 17646232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.